Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02708849 · ClinicalTrials.gov registry record · Phase 1
The Sustained Effects of Ketamine
A Phase 1 study, sponsored by Yale University.
- Terminated
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT02708849 is a Phase 1 study that was terminated before completion, run by Yale University. The registered enrollment target is 3 participants.
The verdict
NCT02708849, a Phase 1 study, was terminated before completion, sponsored by Yale University.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
The purpose of the study is to characterize the effects of a single, sub-anesthetic dose of ketamine in rs-fMRI in healthy subjects. Post-ketamine rs-fMRI data will demonstrate a pattern of increased global brain connectivity (GBC) in fronto-temporal cortex.
Interventions
- DRUG Placebo
- DRUG Ketamine
- DRUG Lamotrigine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2015-06 |
| Est. Completion | 2020-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02708849
The ClinicalTrials.gov registry entry for NCT02708849 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02708849 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02708849 about?
NCT02708849 is a clinical study titled "The Sustained Effects of Ketamine". The purpose of the study is to characterize the effects of a single, sub-anesthetic dose of ketamine in rs-fMRI in healthy subjects. Post-ketamine rs-fMRI data will demonstrate a pattern of increased global brain connectivity (GBC) in fronto-temporal cortex.
What is the current status of trial NCT02708849?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2015-06. Estimated completion is 2020-03.
What interventions are being tested in trial NCT02708849?
The interventions under investigation include: Placebo (DRUG), Ketamine (DRUG), Lamotrigine (DRUG).
Who is sponsoring clinical trial NCT02708849?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.